Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 9, 2002, Pages 2735-2746

  Strumberg, Dirk ^a   Nitiss, John L ^a   Dong, Jiaowang ^a   Walker, Jerrylaine ^a   Nicklaus, Marc C ^a   Kohn, Kurt W ^a   Heddle, Jonathan G ^a   Maxwell, Anthony ^a   Seeber, Siegfried ^a   Pommier, Yves ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CALCIUM ION; CIPROFLOXACIN; CP 115953; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; MITOXANTRONE; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

AMINO ACID SYNTHESIS; ARTICLE; DNA CLEAVAGE; DNA DRUG COMPLEX; DNA SEQUENCE; DRUG BINDING SITE; DRUG MECHANISM; ESCHERICHIA COLI; GENE OVEREXPRESSION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; YEAST;

EID: 0036720073     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.9.2735-2746.2002     Document Type: Article

References (60)

1. Topoisomerase IV catalysis and the mechanism of quinolone action
2. Catalytic inhibitors of DNA topoisomerase II
3. Drug resistance associated with altered DNA topoisomerase II
4. Type II DNA topoisomerases
5. Structural similarities between topoisomerases that cleave one or both DNA strands
6. Structure and mechanism of DNA topoisomerase II
7. A topoisomerase from Escherichia coli related to DNA gyrase
8. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: Relationship with DNA binding affinity and cytotoxicity
9. DNA topoisomerases: Structure, function, and mechanism
10. DNA topoisomerases: Essential enzymes and lethal targets
11. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme
12. DNA gyrase can cleave short DNA fragments in the presence of quinolone drugs
13. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones
14. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons
15. A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine
16. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands
17. Site-specific interaction of DNA gyrase with DNA
18. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism
19. AcrB mutation located at carboxyl-terminal region of gyrase B subunit reduces DNA binding of DNA gyrase
20. DNA gyrase: Purification and catalytic properties of a fragment of gyrase B protein
21. In the presence of subunit A inhibitors DNA gyrase cleaves DNA fragments as short as 20 bp at specific sites
22. Use of a rapid throughput in vivo screen to investigate inhibitors of eukaryotic topoisomerase II enzymes
23. A structural taxonomy of DNA-binding domains
24. Clinical applications of quinolones
25. Mapping the active site tyrosine of Escherichia coli DNA gyrase
26. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli GyrA alters sensitivity to eukaryotic topoisomerase inhibitors
27. Characterization of topoisomerase II-DNA interaction and identification of a DNA-binding domain by ultraviolet laser crosslinking
28. The DNA gyrase-quinolone complex: ATP hydrolysis and the mechanism of DNA cleavage
29. Binding of etoposide to topoisomerase II in the absence of DNA: Decreased affinity as a mechanism of drug resistance
30. Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites
31. Footprinting of yeast DNA topoisomerase II lysyl side chains involved in substrate binding and interdomainal interactions
32. Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP binding
33. Topoisomerase-targeting antitumor drugs: Mechanisms of cytotoxicity and resistance
34. Similarity in the catalysis of DNA breakage and rejoining by type IA and IIA DNA topoisomerases
35. DNA gyrase as a drug target
36. The molecular basis of quinolone action
37. Overexpression and purification of bacterial DNA gyrase
38. Crystal structure of the breakage-reunion domain of DNA gyrase
39. Structure and function of DNA-binding proteins
40. Investigating the biological functions of DNA topoisomerases in eukaryotic cells
41. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction
42. Evidence for a conformational change in the DNA gyrase-DNA complex from hydroxyl radical footprinting
43. Role of the divalent cation in topoisomerase II mediated reactions
44. Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: Trapping the covalent enzyme-DNA complex in an active form
45. The interaction of Escherichia coli topoisomerase IV with DNA
46. DNA topoisomerase II inhibitors
47. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide
48. Tryptic fragments of the Escherichia coli DNA gyrase A protein
49. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage
50. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group
51. The mechanisms of DNA topoisomerases
52. Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions
53. Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions
54. Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin
55. DNA topoisomerases
56. Moving one DNA double helix through another by a type II DNA topoisomerase: The story of a simple molecular machine
57. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex
58. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae
59. Quinolone-resistant mutations of the GyrA gene of Escherichia coli